Information Provided By: 
Fly News Breaks for January 3, 2020
INO
Jan 3, 2020 | 08:06 EDT
H.C. Wainwright analyst Raghuram Selvaraju noted that Inovio Pharmaceuticals disclosed last night in an 8-K filing that the REVEAL 1 Phase 3 trial for VGX-3100 in HPV-16/18-related cervical dysplasia remains on track, but said a Biologics License Application filing to the FDA originally slated for 2021 could be delayed by 12-18 months. The analyst said this delay has no meaningful impact on his valuation of Inovio shares and he reiterated his Buy rating and $13 price target on the stock.
News For INO From the Last 2 Days
There are no results for your query INO
